SavedAdd your journal

Journals / Eurasian Journal of Medical Investigation / 2020 / Cilt: 4 - Sayı: 4

The Clinical Importance of Fibroblast Growth Factor 23 on Breast Cancer Patients

Sener CİHAN
Serdar ARICI
Ruhper CEKİN
Şaban SEÇMELER
Muhammed Mustafa ATCI
Pages
471–476
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The mean FGF 23 level wascalculated as 167.4±177.2 pg/ml in patients group and 63.1±11.4 pg/ml in control group (p=0.0004).Conclusion: Our study suggests that high FGF-FGFR interaction may be causative for breast cancer and is important interms of suggesting the FGF pathway as a new treatment target in breast cancer patients.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To investigate the relation between serum fibroblast growth factor (FGF) 23 levels and clinicopathologicfeatures of breast cancer patients, by comparing healthy control group.Methods: This was a prospective, single-center study.
📊
Key Findings & Data:Newly diagnosed stage 1–4 breast cancer patients and healthycontrol in similar age, without any chronic disease and vitamin D deficiency were enrolled in the study.
💡
Conclusion & Impact:The mean FGF 23 level wascalculated as 167.4±177.2 pg/ml in patients group and 63.1±11.4 pg/ml in control group (p=0.0004).Conclusion: Our study suggests that high FGF-FGFR interaction may be causative for breast cancer and is important interms of suggesting the FGF pathway as a new treatment target in breast cancer patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: To investigate the relation between serum fibroblast growth factor (FGF) 23 levels and clinicopathologicfeatures of breast cancer patients, by comparing healthy control group.Methods: This was a prospective, single-center study. Newly diagnosed stage 1–4 breast cancer patients and healthycontrol in similar age, without any chronic disease and vitamin D deficiency were enrolled in the study. Fibroblastgrowth factor 23 levels were compared between groups.Results: Thirty eight women newly diagnosed stage 1 and 4 patients and 40 healty women were enrolled. The medianage of patients and controls were 54 and 53.1 years. The number of patients were 7 (18.4%), 9 (23.7%), 13 (34.2%), 5(13.2%), 1 (2.6%) and 3 (7.9%) in stage 1A, 2A, 2B, 3A, 3B and stage 4 groups respectively. The mean FGF 23 level wascalculated as 167.4±177.2 pg/ml in patients group and 63.1±11.4 pg/ml in control group (p=0.0004).Conclusion: Our study suggests that high FGF-FGFR interaction may be causative for breast cancer and is important interms of suggesting the FGF pathway as a new treatment target in breast cancer patients.

🔖

Cite This Article

CİHAN, S., ARICI, S., CEKİN, R., SEÇMELER, Ş., ATCI, M. M. (2022). The Clinical Importance of Fibroblast Growth Factor 23 on Breast Cancer Patients. Eurasian Journal of Medical Investigation, Cilt: 4 - Sayı: 4, 471–476. https://ajindex.com/articles/508701

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Miller KD, Goding Sauer A, Ortiz AP, Fedewa SA, Pinheiro PS, Tortolero-Luna G, et al. Cancer Statistics for Hispanics/Latinos, 2018. CA Cancer J Clin 2018;68:425–45
  2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108
  3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin 2019;69:7–34
  4. Marsell R, Jonsson KB. The phosphate regulating hormone fibroblast growth factor-23. Acta Physiol (Oxf) 2010;200:97–106
  5. Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, Kanety H, et al. Klotho: a tumor suppressor and a modulator of the IGF-1 and FGF pathways in human breast cancer. Oncogene 2008;27:7094–105
  6. Abramovitz L, Rubinek T, Ligumsky H, Bose S, Barshack I, Avivi C, et al. KL1 internal repeat mediates klotho tumor suppressor activities and inhibits bFGF and IGF-I signaling in pancreatic cancer. Clin Cancer Res 2011;17:4254–66
  7. Cha SK, Ortega B, Kurosu H, Rosenblatt KP, Kuro OM, Huang CL. Removal of sialic acid involving Klotho causes cell-surface retention of TRPV5 channel via binding to galectin-1. Proc Natl Acad Sci U S A 2008;105:9805–10
  8. Chang Q, Hoefs S, van der Kemp AW, Topala CN, Bindels RJ, Hoenderop JG. The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel. Science 2005;310:490–3
  9. Stewart I, Roddie C, Gill A, Clarkson A, Mirams M, Coyle L, et al. Elevated serum FGF23 concentrations in plasma cell dyscrasias. Bone 2006;39:369–76
  10. Feng S, Wang J, Zhang Y, Creighton CJ, Ittmann M. FGF23 promotes prostate cancer progression. Oncotarget 2015;6:17291– 301
  11. Parish A, Schwaederle M, Daniels G, Piccioni D, Fanta P, Schwab R, et al. Fibroblast growth factor family aberrations in cancers: clinical and molecular characteristics. Cell Cycle 2015;14:2121–8
  12. Tebben PJ, Kalli KR, Cliby WA, Hartmann LC, Grande JP, Singh RJ, et al. Elevated fibroblast growth factor 23 in women with malignant ovarian tumors. Mayo Clin Proc 2005;80:745–51
  13. Loriot Y, Necchi A, Park SH, Garcia-Donas J, Huddart R, Burgess E, et al. Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma. N Engl J Med 2019;381:338–48
  14. Li JR, Chiu KY, Ou YC, Wang SS, Chen CS, Yang CK, et al. Alteration in serum concentrations of FGF19, FGF21, and FGF23 in patients with urothelial carcinoma. Biofactors 2019;45:62–8
  15. Helsten T, Schwaederle M, Kurzrock R. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: b